stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) EBITDA
Organon & Co.'s EBITDA for fiscal 2025 was $1.4B, down 13.6% from $1.7B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.4B. Over the past ten years it has ranged from $1.4B (fiscal 2025) to $5.2B (fiscal 2017) — the current reading is the lowest in ten years. Organon & Co. ranks 15th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.4B | (13.60%) |
| FY2024 | $1.7B | 11.32% |
| FY2023 | $1.5B | (16.22%) |
| FY2022 | $1.8B | (0.50%) |
| FY2021 | $1.8B | (39.04%) |
| FY2020 | $2.9B | (27.08%) |
| FY2019 | $4.0B | (8.47%) |
| FY2018 | $4.4B | (16.07%) |
| FY2017 | $5.2B | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $437.0M | 6.33% |
| Jun 2026 | $411.0M | 30.06% |
| Mar 2026 | $316.0M | 19.25% |
| Dec 2025 | $265.0M | (36.60%) |
| 23 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVO Novo Nordisk A/S compare | $27.2B |
| PFE Pfizer Inc. compare | $20.1B |
| BMY Bristol Myers Squibb Company compare | $14.1B |
| GSK GSK PLC Sponsored ADR compare | $12.2B |
| SNY Sanofi compare | $11.1B |
| BIIB Biogen Inc. compare | $2.3B |
| GRFS Grifols, S.A. compare | $1.9B |
| OGN Organon & Co. | $1.4B |
| AMRN Amarin Corporation PLC compare | −$29.4M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on OGN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement